Update date
31 Dec 2024
Shareable Research Card
ONCY - ONCOLYTICS BIOTECH INC Current Liabilities
This metric view shows ONCY - ONCOLYTICS BIOTECH INC current liabilities history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q4 2024
- Latest reported value
- CA$6,687,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2024
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q4 2024.
- Latest reported value on this page: CA$6,687,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Current Liabilities
Latest reported current liabilities: CA$6,687,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q4 2024
SEC-backed company facts were refreshed from filings filed on 12 Aug 2026.
Benchmark Context
How Current Liabilities compares with peers
ONCOLYTICS BIOTECH INC sits in the upper half of the current current liabilities sample.
Compared with
Compared with 8 companies reporting current liabilities in CAD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 1x the current sample midpoint. Current Liabilities is up about 58% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Aug 2018 to 31 Jan 2026.
- Nearby companies in this sample: Profound Medical Corp. and Versus Systems Inc..
- Current sample position: rank #4 of 8 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
ONCOLYTICS BIOTECH INC: Current Liabilities
Latest period: Q4 2024. Period end: 31 Dec 2024. Units: CAD. Frequency: quarterly.
Current Liabilities is reported in company XBRL facts filed with the SEC.
Metric snapshot
- Latest value
- CA$6,687,000
- Coverage range
- 31 Dec 2016 - 31 Dec 2024
- Fact rows
- 9
What this metric tells you
- Shows reported current liabilities over 31 Dec 2016 - 31 Dec 2024.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 9 SEC fact rows for this metric and issuer.
How to read this chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC source
Source: SEC company facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Current Liabilities levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
ONCOLYTICS BIOTECH INC appears at rank #4 in the latest comparison sample.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | Cronos Group Inc. (cron) | CA$45,493,000 | Instant - 31 Dec 2018 | Open Cronos Group Inc. Current Liabilities |
| 2 | Grace Therapeutics, Inc. (grce) | CA$18,246,000 | Instant - 31 Mar 2019 | Open Grace Therapeutics, Inc. Current Liabilities |
| 3 | Profound Medical Corp. (prof) | CA$10,684,000 | Instant - 31 Dec 2019 | Open Profound Medical Corp. Current Liabilities |
| 4 | ONCOLYTICS BIOTECH INC (oncy) | CA$6,687,000 | Instant - 31 Dec 2024 | Open ONCOLYTICS BIOTECH INC Current Liabilities |
| 5 | Versus Systems Inc. (vs) | CA$5,142,241 | Instant - 31 Dec 2020 | Open Versus Systems Inc. Current Liabilities |
| 6 | MindWalk Holdings Corp. (hyft) | CA$5,030,000 | Instant - 31 Jan 2026 | Open MindWalk Holdings Corp. Current Liabilities |
Metric Details
- Metric
- Current Liabilities (CurrentLiabilities)
- Frequency coverage
-
quarterly
Comparability: Compare annual with annual and quarterly with quarterly
- Taxonomy
- ifrs-full
- Units tracked
- CAD
- History range
-
31 Dec 2016 - 31 Dec 2024
Freshness: From parsed SEC XBRL facts on this page
- Facts on this page
-
9
Source: SEC company facts API
- SEC metric endpoint
- Open SEC company concept
Metric identity
Names, identifiers, and filing context for this profile.
1 identity field
Metric coverage
3 source fields
Source evidence
Original filing metadata and source links for verification.
1 source field
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Current Liabilities, Quarterly (CAD)
Current Liabilities, YoY Quarterly Change (%)
ONCOLYTICS BIOTECH INC Quarterly Current Liabilities (CAD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2024 | CA$6,687,000 | +CA$2,450,000 | +58% | 31 Dec 2024 | 20-F | 07 Mar 2025 | 2024 | FY |
| Q4 2023 | CA$4,237,000 | +CA$292,000 | +7.4% | 31 Dec 2023 | 20-F | 07 Mar 2025 | 2024 | FY |
| Q4 2022 | CA$3,945,000 | +CA$1,255,000 | +47% | 31 Dec 2022 | 20-F | 12 Mar 2024 | 2023 | FY |
| Q4 2021 | CA$2,690,000 | -CA$19,113 | -0.71% | 31 Dec 2021 | 20-F | 03 Mar 2023 | 2022 | FY |
| Q4 2020 | CA$2,709,113 | -CA$10,159,930 | -79% | 31 Dec 2020 | 20-F | 03 Mar 2022 | 2021 | FY |
| Q4 2019 | CA$12,869,043 | +CA$10,054,468 | +357% | 31 Dec 2019 | 20-F | 05 Mar 2021 | 2020 | FY |
| Q4 2018 | CA$2,814,575 | -CA$2,415,093 | -46% | 31 Dec 2018 | 20-F | 06 Mar 2020 | 2019 | FY |
| Q4 2017 | CA$5,229,668 | +CA$1,161,004 | +29% | 31 Dec 2017 | 20-F | 15 Mar 2019 | 2018 | FY |
| Q4 2016 | CA$4,068,664 | 31 Dec 2016 | 20-F | 19 Mar 2018 | 2017 | FY |
* marks a reported value that did not pass the local value check.